Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Sector news Pharmaceuticals - NEC
02:31pMERCK : to Distribute HistoCyte Laboratories Products
DJ
02:01pAlexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
10:02aRoche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
09:51aRoche pays $2.4 billion for rest of cancer expert Foundation Medicine
RE
09:25aPEUGEOT : Sanofi poaches former PSA finance boss Chasseloup de Chatillon
RE
08:34aRoche, Foundation Medicine Reach Definitive Merger Agreement -- Update
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
08:10aSanofi Names Jean-Baptiste Chasseloup de Chatillon as CFO, Executive VP
DJ
07:43aRoche, Foundation Medicine Reach Definitive Merger Agreement
DJ
06/18How U.S. tax reform rewards companies that shift profit to tax havens
RE
06/18Evotec Shares Jump After It Secures Sanofi Agreement
DJ
06/18Indivior shares rise after U.S. court order blocks generic rival drug
RE
06/18INDIVIOR : Wins Legal Battle; Temporarily Blocks Launch of Generic Drug
DJ
06/18SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/16International fund managers turn to financials, tech as trade worries rise
RE
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
06/15Indivior Shares Drop After U.S. Approves Suboxone Generics
DJ
06/15UK's Indivior to seek injunction after rival gets FDA approval for generics
RE
06/15NOVARTIS : Study Shows Jakavi Reduces Blood Clots, Risk of Death
DJ
06/15Roche's Gazyva Cancer Drug Outperforms MabThera
DJ
06/15NOVARTIS : Cohen Probe Is Extended to Lobbying -- WSJ
DJ
06/15SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/15NOVARTIS : Releases Phase 3 Data for Zessly, Erelzi Biosimilars
DJ
06/14ADRs End Mostly Lower; iQiyi, Unilever Trade Actively
DJ
06/14NOVARTIS : Prosecutors Investigating Michael Cohen for Possible Illegal Lobbying
DJ
06/14ABBOTT LABORATORIES : Allergan appoints former Abbott executive to its board
RE
06/14GLAXOSMITHKLINE : Positive Results for ViiV Healthcare's HIV Studies
DJ
06/14SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/14Roche to Present Ocrevus Data Showing Delayed Wheelchair Need in MS Patients
DJ
06/14FDA Rejects Mylan's Asthma Generic Over Deficiencies -- Market Mover
DJ
06/13MERCK AND : Gets FDA Priority Review for Expanded Gardasil Age Range
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/13SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/12JOHNSON & JOHNSON : Accepts Platinum Equity's $2.1 Billion Offer for LifeScan Bu..
DJ
06/12Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials -- Update
DJ
06/12GSK says vaccine business president to leave by year-end
RE
06/12GLAXOSMITHKLINE : Vaccines President to Leave Company by Year-End
DJ
06/12Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials
DJ
06/12AstraZeneca, Eli Lilly to Stop Alzheimer's Treatment Trials
DJ
06/12SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/11Investors ready to resuscitate Johnson & Johnson's ailing stock
RE
06/11Takeda shareholder group aims to block $62 billion Shire deal
RE
06/11Takeda shareholder group aims to block $62 billion Shire deal
RE
06/11Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO
RE
06/11SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/11Roche's Venclexta Plus Rituxan Gets FDA Approval as Leukemia Treatment
DJ
06/08Brewers see future in high tech, weak beer, cannabis brews
RE
06/08ASTRAZENECA : Says EU Grants Marketing Authorization to Tagrisso
DJ
06/08Emirates starts London Stansted flights as rival airports near capacity
RE
06/08NOVO NORDISK A/S : shares fall after report of layoffs
RE
1  2  3  4  5  6  7  8  9  10Next
Financials (€)
Sales 2018 35 204 M
EBIT 2018 7 149 M
Net income 2018 5 138 M
Debt 2018 6 671 M
Yield 2018 2,87%
P/E ratio 2018 17,54
P/E ratio 2019 15,66
EV / Sales 2018 2,83x
EV / Sales 2019 2,67x
Capitalization 93 008 M
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
BAYER-2.22%108 112
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880
AMGEN6.39%122 422
ABBOTT LABORATORIES10.23%110 293
GLAXOSMITHKLINE17.41%102 311
SANOFI-4.41%99 713
ELI LILLY AND COMPANY2.87%94 302
ASTRAZENECA5.12%90 821
BRISTOL-MYERS SQUIBB COMPANY-10.57%89 573
NOVO NORDISK A/S-14.25%85 281
ALLERGAN PLC5.87%58 719
CELGENE CORPORATION-25.18%56 595
SHIRE3.53%49 016
JIANGSU HENGRUI MEDICINE CO LTD43.14%43 378
ASTELLAS PHARMA INC23.03%31 909
TAKEDA PHARMACEUTICAL CO LTD-33.75%31 622
CHUGAI PHARMACEUTICAL CO LTD4.16%30 715